EC Gastroenterology and Digestive System

Introduction: The prevalence of gastroesophageal reflux disease (GERD) varies from 8.8 to 33.1%, and the incidence has a steady upward trend in all regions of the world. GERD is observed in the USA in 29.8% of men and 32.5% of women and in 30% of adults in Western European countries. Dyskinesia of the upper digestive tract accompanies the development of GERD. However, GERD as a polymorbid disease has not been studied enough.

Aim: The aim is to investigate the clinical and diagnostic features of GERD as a polymorbid disease.

Materials and Methods: The examination of 32 patients included clinical, electromyographic and dental examinations. The control group consisted of 16 patients. Statistical analysis was performed using the Statistica-16 software package at p < 0.05.

Results: Electromyographically, there is an increase in retrograde motility of the stomach and esophagus, as well as hypermotor dyskinesia of the duodenum, jejunum and colon. Stomatologically, the presence of carious cavities and gingivitis was revealed.

Conclusion: The features of GERD as a polymorbid disease are the presence of heartburn, motor evacuation disorders indicating an increase in the evacuation function of the stomach. esophagus and the presence of predominantly acid reflux, which determines the development of pathology of the oral cavity.

 Keywords: Gastrointestinal Motor Function; Gastroesophageal Reflux Disease; Dental Manifestations

1. Ivashkin VT and Trukhmanov AS. “Oesophageal disorders”. Moscow: Triada-X (2000).
2. Ivashkin VT., et al. “Gastroesophageal reflux disease. Guidelines in diagnosis and treatment”. Moscow (2013).
3. Trukhmanov AS., et al. “Further guidelines in therapy of gastroesophageal reflux disease”. Gastroenterology and Hepatology: News, Opinions, Training 1 (2013): 2-9.
4. Richter JE and Friedenberg FK. “Gastroesophageal Reflux Disease”. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10^th edition (2015).
5. Mayev IV., et al. “Gastroesophageal reflux disease”. Moscow: GEOTAR-Media (2019).
6. Chatila AT., et al. “Natural history, pathophysiology and evaluation of gastroesophageal reflux disease”. Disease-a-Month 1 (2020): 100848.
7. El-Serag HB., et al. “Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review”. Gut 6 (2014): 871-880.
8. Savarino E., et al. “Epidemiology and natural history of gastroesophageal reflux disease”. Minerva Gastroenterologica e Dietologica 3 (2017): 175-183.
9. Eusebi LH., et al. “Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis”. Gut3 (2018): 430-440.
10. Lazebnik LB., et al. “Results of a multicentre study “Epidemiology of Gastroesophageal Reflux Disease in Russia” (MEGRE)”. Therapeutic Archive1 (2011): 45-50.
11. Bor S., et al. “Prevalence of gastroesophageal reflux disease in Moscow”. Diseases of the Esophagus 2 (2016): 159-165.
12. Gallinger Yu I and Godzhello EA. “Surgical esophageal endoscopy”. Moscow (1999):
13. Dronova OB., et al. “Diagnostics of gastroesophageal reflux disease”. Orenburg (2008):
14. Ivashkin VT and Trukhmanov AS. “Evolution of ideas about the role of disorders of the motor function of the esophagus in the pathogenesis of gastroesophageal reflux disease”. Russian Journal of Gastroenterology, Hepatology, Coloproctology2 (2010): 13-19.
15. Shulpekova Yu O and Ivashkin VT. “Clinical pharmacology of gastroesophageal reflux disease”. RMJ4 (2002): 200-205.
16. Stanghellini V. “Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: Results from the Domestic International Gastroenterology Surveillance Study (DIGEST)”. Scandinavian Journal of Gastroenterology 231 (1999): 20-2
17. Trukhmanov AS and Ivashkina N Yu. “The clinical significance of disorders of the motor function of the esophagus, stomach and duodenum”. Therapeutic Archive8 (2019): 127-134.
18. Dronova OB and Mironchev OA. “Anatomy and endoscopy of esophagogastric junction: a clinical assessment”. Reconstructive and Plastic Surgery 3-4 (2007): 40-42.
19. Trukhmanov AS., et al. “The clinical role of gastrointestinal motor function investigation: the past, present and future”. Russian Journal of Gastroenterology, Hepatology, Coloproctology5 (2013): 4-14.
20. Trukhmanov AS. “Impact of dopamine receptor antagonists on gastrointestinal motor function”. Practicing Physician 9 (2012): 80-83.
21. Storonova OA., et al. “Esophageal clearance disorders at gastroesophageal reflux disease and their treatment options”. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2 (2012): 14-21.
22. Storonova OA., et al. “The role of protective factors of esophageal mucosa in gastroesophageal reflux disease treatment”. Clinical Perspectives of Gastroenterology, Hepatology 5 (2014): 37-42.
23. Namiot Z., et al. “Declined human esophageal mucin secretion in patients with severe reflux esophagitis”. Digestive Diseases and Sciences 12 (1994): 2523-2529.
24. Niv Y and Fass R. “The role of mucin in GERD and its complications”. Gastroenterology and Hepatology 1 (2011): 55-59.
25. Van Roon AH., et al. “Impact of gastro-esophageal reflux on mucin mRNA expression in the esophageal mucosa”. Journal of Gastrointestinal Surgery 8 (2008): 1331-1340.
26. Dent J. “Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy”. Neurogastroenterology and Motility 1 (2008): 91-102.
27. Tsoukali E and Sifrim D. “Investigation of extraesophageal gastroesophageal reflux disease”. Annals of Gastroenterology 4 (2013): 290-295.
28. Wu JC., et al. “Obesity is associated with increased transient lower esophageal sphincter relaxation”. Digestion 132.3 (2007): 883-88
29. Ivashkin VT., et al. “Clinical aspects of functional dyspepsia and efficacy of ganaton (itopride hydrochloride)”. Russian Journal of Gastroenterology, Hepatology, Coloproctology 6 (2009): 17-22.
30. Pauwels A., et al. “The gastric accommodation response to meal determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease”. Neurogastroenterology and Motility 4 (2014): 581-588.
31. Yevsyutina YV and Ivashkin VT. “Microbiome in development of esophageal diseases”. Russian Journal of Gastroenterology, Hepatology, Coloproctology 3 (2016): 11-16.
32. Rumyantseva DE., et al. “Microbiota of the esophagus and stomach in patients with gastroesophageal reflux disease and healthy volunteers”. Russian Journal of Gastroenterology, Hepatology, Coloproctology 4 (2018): 36-46.
33. Rumyantseva DY., et al. “Effect of antisecretory treatment on gastrointestinal microbiota”. Russian Journal of Gastroenterology, Hepatology, Coloproctology1 (2018): 78-88.
34. Lychkova AE., et al. “Electrical activity of the intestine and biliary tract after hemicolectomy and its enteral correction”. Expert Clinic Gastroenterology8 (2015): 17-21.
35. Lazebnik LB and Zvenigorodskaya LA. “Metabolic syndrome and digestive organs”. M: Anacharsis (2009): 84.